title: Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
authors.affiliation: Departments of Epidemiology and Medicine, Prevention Intervention Center, Colleges of Public Health and Medicine, University of Iowa, Iowa City, IA.
authors.forename: Jennifer G
authors.initials: JG
authors.lastname: Robinson
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood*; D000069438:Ezetimibe / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D019821:Simvastatin / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D002097:C-Reactive Protein; D019821:Simvastatin; D000069438:Ezetimibe